期刊文献+

尿脱落细胞FISH检测在恶性血尿病因诊断中的应用 被引量:2

The Application of Fluorescence in Situ Hybridization in the Etiological Diagnosis of Malignant Hematuria
原文传递
导出
摘要 目的:比较尿脱落细胞荧光原位杂交(Fluorescence in situ hybridzation,FISH)检测、细胞学分析和膀胱镜对恶性血尿诊断的临床有效性及应用价值,为建立或完善恶性血尿病因诊断提供理论基础。方法:10例正常人通过FISH技术检测9号染色体p16位点、3号染色体、7号染色体及17号染色体的变异情况,建立FISH检测尿脱落细胞的方法学平台及标准检测方法同时确立阈值。同时收集100例血尿患者晨尿同步进行细胞学分析、膀胱镜检查及FISH检测。以组织病理确诊为膀胱尿路上皮癌为金标准,评估FISH诊断的特异度和敏感度及与膀胱癌发生及发展的关系。结果:FISH诊断尿路上皮癌的特异度为86.1%,敏感度为89.1%;尿细胞学诊断的特异度为97.2%,敏感度为23.4%。两者相比,敏感度差异有统计学意义(P<0.05),而特异度差异无统计学意义(P>0.05)。结论:与尿细胞学相比,FISH在恶性血尿病因的诊断中具有较高的灵敏度和相似的特异度,同时无创快速,可作为筛查和诊断尿路上皮癌的新方法。 Objective: To evaluate the effectivity and value of fluorescence in situ hybridization(FISH) technique in the diagnosis of malignant hematuria, meanwhile to provide the theoretical basis for establishing or impro ving the diagnosis of malignant hematuria. Methods:Labeled probes for chromosomes 3, 7, 9 and 17 were used to assess chromosomal abnormalities by FISH from 10people without haematuria and established the threshold, the other 100 urine samples from people with haematuria were analyzed by FISH and cytology at the same time. The gold standard was pathology diagnosis. The sensitivity and specificity of FISH were evaluated and compared with Cytological examination. Results:The sensitivity of FISH and cytology in detection urothelial cancer are 74.7 % and 46.0% respectively and the specificity are 92.3% and 100% respectively. When comparing the two examination there is a significant difference between the sensitivity of FISH and cytology(P〈0.05). Conclusions: Compared to cytological examination the FISH assay has a higher sensitivity and a similar specificity in the detection of urotheli al cancer, and the non-in-vasiveness,the fastness making it could be used as a new method in the early detection of urothelial cancer.
出处 《临床泌尿外科杂志》 北大核心 2011年第12期912-915,918,共5页 Journal of Clinical Urology
关键词 膀胱肿瘤 恶性血尿 荧光原位杂交技术 尿脱落细胞学 bladder cancer malignant hematuria fluorescence in situ hybridization cytological examination
  • 相关文献

参考文献13

  • 1van Rhijn B W, van der Poel H G, van der Kwast T H. Urine markers for bladder cancer surveillance: a systematic review[J]. Eur Urol, 2005, 47(6): 736-748.
  • 2Brown J, Jawad M, Twigg S R, etal. A cryptiet(5; 11) (q35;p15.5)in 2 children with a cute myeloid leukemia with apparently normal karyotypes, identified by a multiplex fluorescence in situ hybridization telomere assay[J]. Blood, 2002, 99 (7) : 2526-2531.
  • 3Delhanty J D, Harper J C, Ao A, et al. Multicolour FISH detects frequent chromosomal mosaicism and chaotic division in normal preimplantation embryos from fertile patients[J]. Hum Genet, 1997, 99:755-760.
  • 4Jemal A, Siegel R, Ward, et al. Cancer statistics, 2008[J]. CA Cancer J Clin, 2008, 58(2) :71-96.
  • 5Sokolova I A, Hailing KC. Jenkins R B, et al. The development of a multitarget multicolor fluorescence in situ hybridization assay for the dectection of urothelial carcinoma in urine[J]. J Mol Diagn, 2000, 2(3):116-123.
  • 6Degtyar P, Neulander E, Zirkin H, et al. Fluorescence in situ hybridization performed on exfoliated urothelial cells in patients with transitional cell carcinoma of the bladder[J]. Urology, 2004, 63(2):398 -401.
  • 7Sarosdy M F, Kahn P R, Ziffer M D, etal. Evaluation of a multitarget fluorescent in situ hybridization (FISH) assay in the initial diagnosis of bladder cancer in patients with hematuria[J]. J Urol, 2004, 171 (Suppl) : 66.
  • 8Maria C, Aleksandra B K, Edyta B, et al. Application of multiplex FISH, CGH and MSSCP techniques for cytogenetic and molecular analysis of transitional cell carcinoma (TCC) cells [J]. J Appl Genet, 2006, in voided urine specimens 47(3) :73-275.
  • 9Luo B, Li W, Deng C H, et al. Utility of fluorescence in situ hybridization in the diagnosis of upper u- rinary tract urothelial carcinoma[J]. Cancer Genet Cytogenet, 2009, 189(2):93-97.
  • 10Brian J Y, Marek S, Ryan H, et al. Reflex urovysion testing of bladder cancer surveillance patients with e- quivocal or negative urine cytology. A prospective study with focus on the natural history of anticipatory positive findings[J]. Am J Clin Pathol, 2007, 127(2): 295-301.

二级参考文献18

  • 1Sokolova I A,Halling K C,Jenkins R B, et al. The development of a multitarget multicolor fluotescence in situ hybridization assay for the dectection of urothelial carcinoma in urine[J].J Mol Diagn, 2000, 2 (3) : 116-123.
  • 2Maria C, Aleksandra B K, Edyta B, et al. Application of multiplex FISH, CGH and MSSCP techniques for cytogenetic and molecular analysis of transitional cell carcinoma (TCC) cells in voided urine specimens[J]. J Appl Genet, 2006, 47(3):73-275.
  • 3Brian J Y, Marek S, Ryan H, et al. Reflex urovysion testing of bladder cancer surveillance patients with equivocal or negative urine cytology. A prospective study with focus on the natural history of anticipatory positive findings [J]. Am J Clin Pathol, 2007, 127:295-301.
  • 4Sarosdy M F, Kahn P R, Ziffer M D, et al. Evaluation of a multitarget fluorescent in-situ hybridization (FISH) assay in the initial diagnosis of bladder cancer in patients with hematuria[J]. J Urol, 2004, 171(Suppl) : 66.
  • 5Peter RIESZ, Gabor LOTZ, Csilla PASKA, et al. Detection of bladder cancer from the urine using fluorescence in situ hybridization technique[J].Pathology Ontology Resareh, 2007, 13(3) :187-194.
  • 6Skacel M, Fahmy, Brainard J, et al. Multitarget fluorescence in situ hybridization assay dectects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology [J]. J Urol, 2003, 169:2101-2105.
  • 7Raitanen M P, Kaasinen E, Lukkarinen O, et al. Analysis of false-positive BAT Stat test results in patients followed up for bladder cancer [J]. Urology, 2001, 57:680-684.
  • 8Mian C, Lodde M, Comploj E, et al. Multiprobe fluorescence in situ hybridization:prognostic perspectives in superficial bladder cancer[J]. Journal of Clinical Pathology, 2006, 59:984-987.
  • 9Degtyar P, Neulander E, Zirkin H, et al. Fluorescence in situ hybridization performed on exfoliated urothelial cells in patients with transitional cell carcinoma of the bladder. Urology, 2004, 63 : 398-401.
  • 10Tsukamoto M, Matsuyama H, Obaket, et al. Numerical aberration of chromosome 9 in bladder cancer: a possible prognostic marker for early tumor recurrence. Cancer Genet Cytogenet, 2002, 134: 41-45.

共引文献19

同被引文献17

  • 1赵洁,金讯波,夏庆华,孙鹏,张红丽,张文.荧光原位杂交(FISH)技术在尿路上皮癌诊断中的应用研究[J].泌尿外科杂志(电子版),2011,3(2):7-11. 被引量:1
  • 2CAMPBELL M F, WEIN A J, KAVOUSSI L R. Campbell-Walsh urology[M]. 10th ed. Philadelphia, PA:Elsevier Saunders,2012:4.
  • 3KAZI SN, BENZ RL. Work-up of hematuria[J]. Prim Care,2014,41(4):737-748.
  • 4MARGULIS V, SAGALOWSKY AI. Assessment of hematuria[J]. Med Clin North Am,2011,95(1):153-159.
  • 5MIAH S, CATTO JWF. Haematuria[J]. Surgery(Oxford),2010,28(12):589-593.
  • 6FRAGKOPOULOU C, ROSARIO DJ. Haematuria[J].Surgery(Oxford),2013,31(10):509-515.
  • 7KHADRA M H, PICKARD R S, CHARLTON M, et al. A prospective analysis of 1,930 patients with hematuria to evaluate current diagnostic practice[J]. J Urol,2000,163(2):524-527.
  • 8JONES JS. DNA-based molecular cytology for bladder cancer surveillance[J]. Urology,2006,67(3 Suppl 1):35-47.
  • 9MIAN C, MAZZOLENI G, VIKOLER S, et al. Fluorescence in situ hybridisation in the diagnosis of upper urinary tract tumours[J]. Eur Urol,2010,58(2):288-292.
  • 10ROUPRET M, BABJUK M, COMPERAT E, et al. European guidelines on upper tract urothelial carcinomas: 2013 update[J]. Eur Urol,2013,63(6):1059-1071.

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部